0.15%
5.49%
12.31%
20.57%
19.74%
-8.86%
-7.32%
AI Spotlight on BMY
Company Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma.In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML.It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
The company was formerly known as Bristol-Myers Company.The company was founded in 1887 and is headquartered in New York, New York.
Market Data
| Last Price | 59.14 |
| Change Percentage | 0.15% |
| Open | 59.29 |
| Previous Close | 59.05 |
| Market Cap ( Millions) | 119947 |
| Volume | 6327164 |
| Year High | 61.1 |
| Year Low | 39.35 |
| M A 50 | 57.6 |
| M A 200 | 49.83 |
Financial Ratios
| FCF Yield | 11.51% |
| Dividend Yield | 4.09% |
| ROE | -36.26% |
| Debt / Equity | 299.85% |
| Net Debt / EBIDTA | 860.22% |
| Price To Book | 7.0 |
| Price Earnings Ratio | -16.52 |
| Price To FCF | 8.69 |
| Price To sales | 2.53 |
| EV / EBITDA | 32.32 |
News
- Jan -30 - Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
- Jan -30 - Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Jan -29 - 10 Undervalued Dividend Growth Stocks: January 2025
- Jan -29 - 3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average
- Jan -27 - Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
- Jan -25 - Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy
- Jan -24 - Bloomsbury inks new long-term supply deal with Amazon
- Jan -19 - Top 4 Immunology Stocks Poised For Growth In 2025
- Jan -17 - Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
- Jan -15 - Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
- Jan -14 - Feedback on schizophrenia treatment has been great, says Bristol Myers Squibb CEO
- Jan -13 - Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
- Jan -13 - Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
- Jan -13 - ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
- Jan -10 - Look Out, Interest Rate Cuts Could Be Over: Buy These High-Yield Passive Income Stars Now
- Jan -09 - Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade
- Jan -09 - Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills
- Jan -09 - This Unpopular Dividend Stock Is a Buy
- Jan -08 - Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
- Jan -06 - The Magnificent 7 Blue-Chip Dividend Stocks to Buy in 2025 and Hold Forever
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Medicines
Expected Growth : 9.33 %
What the company do ?
Innovative Medicines from Bristol-Myers Squibb Company develops and commercializes novel treatments for serious diseases, including cancer, immunology, and fibrosis.
Why we expect these perspectives ?
Bristol-Myers Squibb's Innovative Medicines segment growth of 9.33% is driven by strong sales of Eliquis, Opdivo, and Orencia, as well as the launch of new products such as Zeposia and Reblozyl. Additionally, the company's strategic acquisitions, including Celgene, have expanded its portfolio and contributed to growth.
Bristol-Myers Squibb Company Products
| Product Range | What is it ? |
|---|---|
| Opdivo | A programmed death-1 (PD-1) inhibitor used to treat various types of cancer, including melanoma, lung cancer, kidney cancer, and others. |
| Eliquis | An oral factor Xa inhibitor used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. |
| Orencia | A selective T-cell costimulation modulator used to treat rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. |
| Yervoy | A monoclonal antibody used to treat unresectable or metastatic melanoma. |
| Sprycel | A tyrosine kinase inhibitor used to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. |
| Empliciti | A humanized monoclonal antibody used to treat multiple myeloma. |
| Reblozyl | A luspatercept-aamt used to treat anemia in patients with beta thalassemia. |
Bristol-Myers Squibb Company's Porter Forces
Threat Of Substitutes
The threat of substitutes for Bristol-Myers Squibb Company is medium due to the presence of alternative treatments and generic drugs in the market.
Bargaining Power Of Customers
The bargaining power of customers is low due to the lack of negotiating power of individual patients and the complexity of pharmaceutical products.
Bargaining Power Of Suppliers
The bargaining power of suppliers is medium due to the presence of multiple suppliers of raw materials and the company's dependence on them.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and high research and development costs.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of several large pharmaceutical companies competing in the market, leading to high marketing and advertising expenses.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 58.49% |
| Debt Cost | 3.95% |
| Equity Weight | 41.51% |
| Equity Cost | 6.17% |
| WACC | 4.87% |
| Leverage | 140.89% |
Bristol-Myers Squibb Company : Quality Control
Bristol-Myers Squibb Company passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LLY | Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, … |
| MRK | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas … |
| GILD | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, … |
| AMGN | Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥈
Gilead Sciences
A-Score
1-Year Total Return ->
🥉
Merck
A-Score
1-Year Total Return ->
4
J&J
A-Score
1-Year Total Return ->
5
Lilly
A-Score
1-Year Total Return ->
6
